We have screened 40 prospective samples (11 NSCLC, 27 CRC, 2 MELA; S2 Table) with NGS as well as with the relevant orthogonal assay for the actionable mutations in BRAF, EGFR, KRAS and NRAS. In 20 samples, a mutation was detected with targeted NGS (coverage >300 and VAF >5%) and confirmed by the standard assay (S7 Table). This evidence concerns the gene BRAF and non-small cell lung carcinoma.